Radius Pharmaceuticals Licenses Abaloparatide Rights to Pharmanovia for Asia Pacific Markets

Radius Pharmaceuticals, a subsidiary of Radius Health, has announced a significant licensing agreement with Pharmanovia. This partnership grants Pharmanovia exclusive rights to commercialize abaloparatide, a bone-forming agent for osteoporosis, in various Asia Pacific territories including China, Singapore, and Thailand. Radius markets abaloparatide in the U.S. as TYMLOS®.

Scott Briggs, CEO of Radius, expressed enthusiasm for the partnership, highlighting it as a step towards expanding treatment access. James Burt, Pharmanovia's CEO, praised the deal, underscoring the strength of their commercial platform, particularly in China.

The agreement includes an upfront payment to Radius and potential regulatory and commercial milestones. Radius will also earn tiered royalties on net sales.